Adaptive Biotechnologies COO trades 38K shares
Adaptive Biotechnologies President and COO Julie Rubinstein exercised stock options and sold shares in pre-planned transactions.
Rhea-AI Filing Summary
Adaptive Biotechnologies President and COO Julie Rubinstein exercised stock options and sold shares in pre-planned transactions. She exercised options to acquire 29,444 shares of common stock at $7.27 per share, then sold 38,120 shares of common stock in open-market trades at weighted average prices of $14.45 and $14.60 per share.
All transactions were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, indicating they were pre-scheduled. Following these trades, Rubinstein directly holds 447,202 shares of Adaptive Biotechnologies common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
6 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
38,120 shs ($554K)
Approx. gross sale proceeds
$554K
Approx. exercise cost
$214K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 19,060 | $14.60 | $278K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 19,060 | $14.45 | $275K |
Holdings After Transaction:
Stock Option (right to buy) — 81,719 contracts (Direct);
Common Stock — 447,202 shares (Direct)
Footnotes (4)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The option is fully vested and exercisable.
Key Figures
Options exercised: 29,444 shares
Exercise price: $7.27/share
Shares sold: 38,120 shares
+4 more
7 metrics
Options exercised
29,444 shares
Common stock acquired via option exercises at $7.27
Exercise price
$7.27/share
Stock Option (right to buy) for common stock
Shares sold
38,120 shares
Open-market sales of common stock across two days
Sale price 1
$14.45/share
Weighted average price for 19,060 shares sold on April 1
Sale price 2
$14.60/share
Weighted average price for 19,060 shares sold on April 2
Post-trade holdings
447,202 shares
Common stock directly held after all reported transactions
Remaining options
81,719 options
Stock options remaining after exercises, expiring February 7, 2029
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), fully vested and exercisable, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
fully vested and exercisable financial
"The option is fully vested and exercisable."
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ADPT President and COO Julie Rubinstein report?
Julie Rubinstein reported exercising options for 29,444 shares at $7.27 and selling 38,120 common shares in open-market trades. These transactions were routine equity compensation exercises combined with partial share sales rather than new open-market share purchases.
Were Julie Rubinstein’s ADPT stock sales under a Rule 10b5-1 trading plan?
Yes. A footnote states that all transactions in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing.
What stock options did Julie Rubinstein exercise in this ADPT Form 4?
Rubinstein exercised stock options labeled as a “Stock Option (right to buy)” for 14,722 shares on each of two dates, totaling 29,444 shares, at an exercise price of $7.27 per share. A footnote notes that the option is fully vested and exercisable.
Does this ADPT Form 4 show remaining option holdings for Julie Rubinstein?
Yes. After the option exercises, one derivative entry shows 81,719 stock options following the transaction, with an expiration date of February 7, 2029. This indicates Rubinstein continues to hold a meaningful remaining option position beyond the shares just exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
